Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to learn if BMS-354825 will have activity,
defined by hematologic response, in subjects who have accelerated phase chronic myeloid
leukemia (CML) who are resistant to or intolerant to imatinib mesylate. The safety of this
treatment will also be studied.